Monthly Archives: January 2012

Calculating the Cost of R&D: Defending Tufts Research

Estimates of what it takes to deliver a compound to market are more than an academic exercise — such data has an increasingly important on-the-ground impact on industry revenues,  because if you cannot justify your costs how do you expect to prevail on price?   
Posted in Op-Ed, pricing, R&D | Tagged , , , , , | 1 Comment

Humana CEO: Keep People Out of Hospitals

Outgoing CEO Michael McCallister said one of Humana’s primary strategies going forward is to keep patients out of hospitals and other healthcare institutions, when possible.
Posted in Strategy | Leave a comment

My Healthcare's Better Than Your Healthcare

by Soliant Health Long before the current debate on health care started, there was a different war brewing. For decades, people have been fighting over which program and plan is best: healthcare provided to government workers, military personnel or civilians?
Posted in Strategy | Leave a comment

The Rising Clout of the Patient

by Sarah Krüg In 2011, the patient’s clout as a stakeholder was firmly established, as reflected in several industry conferences. What’s next for the patient in 2012?
Posted in Events, leadership, Meetings, Patient Communication, patient education, social media, Strategy, Technology | Tagged , , | 1 Comment

Arise Sir Andrew (Witty)

Big Pharma received a nod in the UK’s New Year’s Honours List this week when a knighthood was duly bestowed upon GSK’s Andrew Witty — making him ‘Sir Andrew’ to you and me. For once, though, receiving such an honor did not exactly place him in totally exalted company.
Posted in Global, leadership, Op-Ed | Tagged , , , | Leave a comment
  • Categories

  • Meta